Progressive's once-predictable dividend policy swerved sharply in 2024 with a one-time spike, only to be slashed again in ...

Faruqi & Faruqi, LLP is investigating Elevance Health for misleading investors about rising Medicaid costs between April and ...

Allspring Global Investments Holdings LLC reduced its stake in Prologis by 1% in Q1, selling 4,536 shares. Other ...

Cidel Asset Management reduced its Citigroup holdings by 9.1% in the first quarter, selling 3,032 shares valued at $2.16 ...

Boeing's stock slipped 1.1% despite a notable 76% drop in trading volume, closing at $207.26 after hitting a low of $207.70.

DAVENPORT & Co LLC slightly boosted its stake in The TJX Companies by purchasing 2,428 additional shares in Q1, bringing ...

KBC Group NV increased its stake in Deere & Company by 1% in Q1, signaling steady institutional interest in the industrial ...

Spire Wealth Management increased its Airbnb holdings by 40.1% in Q1, buying an additional 260 shares. This brings their ...

Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...

Lockheed Martin will release its second quarter 2025 earnings results on July 22, with a live webcast at 11 a.m. ET. James ...

Bessemer Group significantly trimmed its investment in Regeneron Pharmaceuticals during the first quarter, slashing its stake ...

Bristol-Myers Squibb is running a rigorous Phase 2/3 clinical trial on ozanimod, aiming to help children with moderate to severe ulcerative colitis who haven’t responded to conventional treatments.